In spite of the share price going up more than 30% since early 2016 after disappointing results for Bristol-Myers Squibb (NYSE:BMY) in lung cancer in the Checkmate-026 study, I still think that Merck & Co.(NYSE:MRK) offers a compelling risk/reward with the stock trading at 15x P/E 2018.
Thus, in this article, I will focus on a quantitative valuation of the company to assess why MRK is trading at an attractive valuation.
Base Case
DCF analysis, with inputs slightly below analyst estimates, shows that MRK's risk/reward is compelling.
I used the Excel template offered by Bloomberg, but I adjusted consensus estimates to reflect my view on MRK's Immunotherapy (I/O) opportunity in NSCLC (Non-small cell lung cancer), which is the most important element to assessing the long-term valuation of the company.

